TREA

88469477 - HYLEUKIN-7

Follow

Information

  • Trademark
  • 88469477
  • Serial Number
    88469477
  • Filing Date
    June 12, 2019
    5 years ago
  • Transaction Date
    January 25, 2021
    3 years ago
  • Status Date
    January 25, 2021
    3 years ago
  • Published for Opposition Date
    April 28, 2020
    4 years ago
  • Location Date
    June 23, 2020
    4 years ago
  • Status Code
    606
  • Current Location
    INTENT TO USE SECTION
    Employee Name
    O'BRIEN, JENNIFER LYNN
  • Attorney Docket Number
    3395.0003
    Attorney Name
    James R Menker
    Law Office Assigned Location Code
    N20
  • Owners
Information
Mark Drawing Code
4000
Mark Identification
HYLEUKIN-7
Case File Statements
  • GS0051: Antibiotics; Anti-cancer preparations; Anti-inflammatory preparations, namely, anti-inflammatory gels, ointments, salves, sprays, creams, pills, powders, granules, tablets, capsules, depots, suppository, syrup, tinctures and emulsion; Antiviral agent against human papilloma virus; Blood solvent for medical purposes, namely, blood plasma, albumin, globulin, fibrinogen, thrombocyte and platelets; Cardiovascular pharmaceutical preparations for the treatment and prevention of heart and vascular diseases; Dermatological pharmaceutical products; DNA vaccines; Drugs for medical purposes, namely, pharmaceutical drug preparations for the treatment and prevention of human papilloma virus infectious disease, cancer and cervical intraepithelial neoplasia; Injectable pharmaceuticals for medical purposes, namely, for the treatment and prevention of human papilloma virus infectious disease, cancer and cervical intraepithelial neoplasia; Medicines for sensory organs, namely, pharmaceutical preparations for the prevention, treatment, and cure of diseases and conditions impacting the eyes, ears, nose, mouth and nervous system; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical preparations and compositions for the treatment and prevention of cancer; Pharmaceutical preparations for activating cellular function; Pharmaceutical preparations for anticancer immunotherapy; Pharmaceutical preparations for digestive organs, namely, for the prevention, treatment, and cure of diseases and conditions impacting digestive organs; Pharmaceutical preparations for gene therapy; Pharmaceutical preparations for immunomodulatory purposes, namely, for the regulation of immune functions; Pharmaceutical preparations for immunotherapy; Pharmaceutical preparations for preventing and treating obese; Pharmaceutical preparations for regulating the immune system; Pharmaceutical preparations for the prevention of osteoporosis; Pharmaceutical preparations for the treatment of autoimmune diseases; Pharmaceutical preparations for the treatment of cardiovascular disease; Pharmaceutical preparations for the treatment of cervical cancer; Pharmaceutical preparations for the treatment of cervical intraepithelial neoplasia; Pharmaceutical preparations for the treatment of cervical pre-cancer; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of head and neck cancer; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical preparations for the treatment of multiple sclerosis; Pharmaceutical preparations for the treatment of osteoporosis; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating malignant tumours; Pharmaceutical preparations for urogenital organs; Pharmaceutical preparations for wounds; Pharmaceutical products and preparations, namely, for the treatment and prevention of human papilloma virus infectious disease, cancer and cervical intraepithelial neoplasia; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of cancer; Pharmaceutical products for the treatment of infectious diseases; Pharmaceutical products for the treatment of viral and infectious diseases; Pharmaceutical products for the treatment of viral diseases; Preventive vaccines; Preventive vaccines against human papilloma virus infections; Therapeutic vaccines; Vaccines; Pharmaceutical preparations for the treatment of lymphopenia; Immunoglobulin fusion protein pharmaceutical preparations, namely, antibodyfusion proteins for the treatment of cancer
  • PM0001: HYLEUKIN- SEVEN
Case File Event Statements
  • 1/25/2021 - 3 years ago
    26 - ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED Type: MAB6
  • 1/25/2021 - 3 years ago
    25 - ABANDONMENT - NO USE STATEMENT FILED Type: ABN6
  • 6/23/2020 - 4 years ago
    24 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT Type: NOAM
  • 4/28/2020 - 4 years ago
    23 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 4/28/2020 - 4 years ago
    22 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 4/8/2020 - 4 years ago
    21 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 3/25/2020 - 4 years ago
    20 - ASSIGNED TO LIE Type: ALIE
  • 3/19/2020 - 4 years ago
    19 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 3/18/2020 - 4 years ago
    18 - EXAMINER'S AMENDMENT ENTERED Type: XAEC
  • 3/18/2020 - 4 years ago
    17 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN
  • 3/18/2020 - 4 years ago
    16 - EXAMINERS AMENDMENT E-MAILED Type: GNEA
  • 3/18/2020 - 4 years ago
    15 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA
  • 2/24/2020 - 4 years ago
    14 - TEAS CHANGE OF CORRESPONDENCE RECEIVED Type: TCCA
  • 2/24/2020 - 4 years ago
    13 - APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Type: CHAN
  • 2/24/2020 - 4 years ago
    12 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Type: ARAA
  • 2/24/2020 - 4 years ago
    11 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Type: REAP
  • 2/24/2020 - 4 years ago
    10 - TEAS CHANGE OF OWNER ADDRESS RECEIVED Type: COAR
  • 2/24/2020 - 4 years ago
    9 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 2/24/2020 - 4 years ago
    8 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 2/24/2020 - 4 years ago
    7 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 8/26/2019 - 5 years ago
    6 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 8/26/2019 - 5 years ago
    5 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 8/26/2019 - 5 years ago
    4 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 8/20/2019 - 5 years ago
    3 - ASSIGNED TO EXAMINER Type: DOCK
  • 6/24/2019 - 5 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM Type: NWOS
  • 6/15/2019 - 5 years ago
    1 - NEW APPLICATION ENTERED IN TRAM Type: NWAP